Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
View Patent ↗Recombinant cells and methods are provided that relate to the use of isolated, engineered recombinant cells to directly or indirectly treat diseases or disorders in a mammalian host such as endocrine, gastrointestinal or autoimmune disorders. A recombinant cell is provided that comprises a signal sequence and a promoter, wherein: the signal sequence is capable of regulating signal-dependent expression of a target nucleic acid in a host or is capable of regulating signal-dependent expression of a target nucleic acid in response to an environmental stimulus, the cell is derived from an enteric or a commensal bacterium, and the target nucleic acid encodes a mammalian factor that promotes normal functioning of a physiological process in the host or is effective in preventing onset, establishment, or spread of a non-infectious disease in the host. The recombinant cell is administered to the host to treat the disease or disorder.
1. A method of treating a mammalian host who has diabetes or metabolic syndrome comprising the step of:
administering orally to the mammalian host a recombinant Lactobacillus bacterium that comprises a promoter and coding sequence that encodes GLP-1(1-37),
wherein the promoter and coding sequence that encodes GLP-1(1-37) comprise SEQ ID NO: 19, said GLP-1(1-37) is expressed and secreted by the recombinant Lactobacillus bacterium in the intestine of the mammalian host, and intestinal epithelial cells of the mammalian host differentiate into glucose responsive insulin secreting cells.
2. The method of claim 1 , wherein the recombinant Lactobacillus cell is administered in an amount of at least about 2×10 10 CFU/kg of the host's weight.
3. The method of claim 2 , wherein the recombinant Lactobacillus cell is administered in an amount selected from group consisting of at least about 5 g/day to about 15 g/day, and at least about 50 mg/day to about 150 mg/day.
4. A method of treating a mammalian host who has diabetes comprising the step of:
administering orally to the mammalian host a recombinant Lactobacillus bacterium that comprises a promoter and coding sequence that encodes GLP-1(1-37),
wherein the promoter and coding sequence that encodes the signal protein or peptide GLP-1(1-37) comprise SEQ ID NO: 19, said GLP-1(1-37) is expressed and secreted by the recombinant Lactobacillus bacterium in the intestine of the mammalian host, and intestinal epithelial cells of the mammalian host differentiate into glucose responsive insulin secreting cells.
5. The method of claim 1 wherein the mammalian host is a human.
6. The method of claim 4 , wherein the mammalian host has type 1 diabetes.
7. The method of claim 6 , wherein the mammalian host is a human.
8. The method of claim 4 , wherein the mammalian host is a human.
9. The method of claim 4 , wherein the recombinant Lactobacillus cell is administered in an amount of at least about 2×10 10 CFU/kg of the host's weight.
10. The method of claim 4 , wherein the recombinant Lactobacillus cell is administered in an amount selected from group consisting of at least about 5 g/day to about 15 g/day, and at least about 50 mg/day to about 150 mg/day.
11. The method of claim 4 , wherein the mammalian host has type 2 diabetes.
12. The method of claim 11 , wherein the mammalian host is a human.
13. A method of preventing or reducing hyperglycemia in a mammalian host who has diabetes or metabolic syndrome comprising the step of:
administering orally to the mammalian host a therapeutically effective amount of a recombinant Lactobacillus bacterium that comprises a promoter and coding sequence that encodes GLP-1(1-37),
wherein the promoter and coding sequence that encodes GLP-1(1-37) comprise SEQ ID NO: 19, said GLP-1(1-37) is expressed and secreted by the recombinant Lactobacillus bacterium in the intestine of the mammalian host, and intestinal epithelial cells of the mammalian host differentiate into glucose responsive insulin secreting intestinal cells.
14. The method of claim 13 , wherein the recombinant Lactobacillus cell is administered in an amount of at least about 2×10 10 CFU/kg of the host's weight.
15. The method of claim 13 , wherein the recombinant Lactobacillus cell is administered in an amount selected from group consisting of at least about 5 g/day to about 15 g/day, and at least about 50 mg/day to about 150 mg/day.
16. The method of claim 13 , wherein the mammalian host is a human.
17. The method of claim 13 , wherein the mammalian host has type 1 diabetes.
18. The method of claim 17 , wherein the mammalian host is a human.
19. The method of claim 13 , wherein the mammalian host has type 2 diabetes.
20. The method of claim 19 , wherein the mammalian host is a human.